TaiGen Biopharmaceuticals Holdings (ROCO:4157) LT-Debt-to-Total-Asset: 0.01 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4157 TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
59 GF Score
Price NT$8.90
GF Value NT$34.17
Valuation Significantly Undervalued
View Full Analysis

What is TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset?

TaiGen Biopharmaceuticals Holdings ROCO:4157 +0.34% 59 LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus rates ROCO:4157 with a GF Score™ of 59/100 and a GF Value™ of NT$34.17 (Significantly Undervalued).

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. TaiGen Biopharmaceuticals Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.01.

TaiGen Biopharmaceuticals Holdings's long-term debt to total assets ratio declined from Dec. 2024 (0.04) to Dec. 2025 (0.01). It may suggest that TaiGen Biopharmaceuticals Holdings is progressively becoming less dependent on debt to grow their business.

TaiGen Biopharmaceuticals Holdings  (ROCO:4157) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset Related Terms

TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for TaiGen Biopharmaceuticals Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.02 0.05 0.04 0.01

TaiGen Biopharmaceuticals Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.03 0.03 0.03 0.01
ROCO:4157
59GF Score
TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiGen Biopharmaceuticals Holdings LT-Debt-to-Total-Asset Calculation

TaiGen Biopharmaceuticals Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=8.622/1167.254
=0.01

TaiGen Biopharmaceuticals Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=8.622/1167.254
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a LT-Debt-to-Total-Asset of 0.01 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors.
Is TaiGen Biopharmaceuticals Holdings' LT-Debt-to-Total-Asset too high?
TaiGen Biopharmaceuticals Holdings' current LT-Debt-to-Total-Asset is 0.01. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' LT-Debt-to-Total-Asset compare to VRTX and REGN?
TaiGen Biopharmaceuticals Holdings' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. TaiGen Biopharmaceuticals Holdings's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.17, compared to a current price of NT$8.90 — trading 74% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?

Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued. The current stock price of NT$8.90 is trading 74% below its estimated GF Value™ of NT$34.17. GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.

Key valuation signals for ROCO:4157:

  • LT-Debt-to-Total-Asset: 0.01
  • GF Value™: NT$34.17 vs. price of NT$8.90 (74% below fair value)
  • GF Score™: 59/100

No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiGen Biopharmaceuticals Holdings Business Description

Address No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score

Get the complete analysis for ROCO:4157

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$8.90
Price
NT$34.17
GF Value